ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
85,245
0,16%
Bitcoin
63 297,24
1,00%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Harpoon Therapeutics Inc (HARP)

  7. Harpoon Therapeutics Inc (HARP) Actualités

HARP

Harpoon Therapeutics (HARP)

Harpoon Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:HARP
DateHeureSourceTitreSymboleSociété
11/03/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HARPHarpoon Therapeutics Inc
11/03/202414h55Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:HARPHarpoon Therapeutics Inc
11/03/202414h46Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:HARPHarpoon Therapeutics Inc
11/03/202413h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HARPHarpoon Therapeutics Inc
28/02/202413h37Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:HARPHarpoon Therapeutics Inc
08/02/202413h00Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:HARPHarpoon Therapeutics Inc
06/02/202422h15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HARPHarpoon Therapeutics Inc
29/01/202422h52Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:HARPHarpoon Therapeutics Inc
10/01/202421h07PR Newswire (US)Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law FirmNASDAQ:HARPHarpoon Therapeutics Inc
09/01/202412h12IH Market NewsWall Street Highlights: HPE and Juniper Networks in Negotiations, Elliott Invests $1 Billion in Match Group, and MoreNASDAQ:HARPHarpoon Therapeutics Inc
08/01/202413h30Business WireMerck to Acquire Harpoon Therapeutics, Further Diversifying Oncology PipelineNASDAQ:HARPHarpoon Therapeutics Inc
05/01/202423h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HARPHarpoon Therapeutics Inc
26/12/202313h30GlobeNewswire Inc.Harpoon Therapeutics Strengthens Leadership TeamNASDAQ:HARPHarpoon Therapeutics Inc
22/12/202322h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:HARPHarpoon Therapeutics Inc
20/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HARPHarpoon Therapeutics Inc
19/12/202313h30GlobeNewswire Inc.Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers SymposiumNASDAQ:HARPHarpoon Therapeutics Inc
12/12/202302h15GlobeNewswire Inc.Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)NASDAQ:HARPHarpoon Therapeutics Inc
08/12/202322h08Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:HARPHarpoon Therapeutics Inc
24/11/202320h01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HARPHarpoon Therapeutics Inc
09/11/202322h28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HARPHarpoon Therapeutics Inc
09/11/202322h01GlobeNewswire Inc.Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:HARPHarpoon Therapeutics Inc
03/11/202321h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:HARPHarpoon Therapeutics Inc
02/11/202314h15GlobeNewswire Inc.Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:HARPHarpoon Therapeutics Inc
23/10/202313h17GlobeNewswire Inc.Harpoon Therapeutics Announces Up to $150 Million Private PlacementNASDAQ:HARPHarpoon Therapeutics Inc
21/10/202317h31GlobeNewswire Inc.Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023NASDAQ:HARPHarpoon Therapeutics Inc
16/10/202322h05GlobeNewswire Inc.Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023NASDAQ:HARPHarpoon Therapeutics Inc
09/10/202322h17GlobeNewswire Inc.Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023NASDAQ:HARPHarpoon Therapeutics Inc
28/09/202309h00GlobeNewswire Inc.Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual MeetingNASDAQ:HARPHarpoon Therapeutics Inc
15/09/202313h15GlobeNewswire Inc.Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination CohortNASDAQ:HARPHarpoon Therapeutics Inc
13/09/202323h12Dow Jones NewsHarpoon Shares Drop 7.3% as AbbVie Declines License OptionNASDAQ:HARPHarpoon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HARP

Dernières Valeurs Consultées

EU
I2SBT
SA1 2SBTC INAV
COIN
ZODIETH
Zodium
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés